The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.

Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...

There wasn’t evidence that Oxbryta was necessarily the cause — in some cases, malaria or another infection was involved — but according to Pfizer, there was an “imbalance” in deaths and ...

The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...

This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...